Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
38.1M
-
Shares change
-
-1.11M
-
Total reported value, excl. options
-
$827M
-
Value change
-
-$21.7M
-
Put/Call ratio
-
0.51
-
Number of buys
-
48
-
Number of sells
-
-56
-
Price
-
$21.70
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q3 2018
155 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q3 2018.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.1M shares
of 108M outstanding shares and own 35.34% of the company stock.
Largest 10 shareholders include FMR LLC (8.21M shares), Vanguard Group Inc (3.94M shares), BlackRock Inc. (3.93M shares), BB BIOTECH AG (2.2M shares), WASATCH ADVISORS INC (1.93M shares), DIMENSIONAL FUND ADVISORS LP (1.42M shares), SCHRODER INVESTMENT MANAGEMENT GROUP (1.2M shares), STATE STREET CORP (1M shares), CITADEL ADVISORS LLC (778K shares), and SAMLYN CAPITAL, LLC (771K shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.